IDH1 mutations in grade II astrocytomas are associated with unfavorable progression‐free survival and prolonged postrecurrence survival

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Cancer

• Publication date

  2012-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.26298PMID 21717448
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abstract 878: DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma

  2011cited by this paper
• Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.

  2011cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2010cited by this paper
• Segregation of non‐p.R132H mutations in IDH1 in distinct molecular subtypes of glioma

  2010cited by this paper
• Abstract 808: Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology

  2010cited by this paper
• IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas

  2010cited by this paper
• IDH1 mutations in gliomas: when an enzyme loses its grip.

  2010cited by this paper
• IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

  2010cited by this paper
• Molecular classification of low-grade diffuse gliomas.

  2010cited by this paper
• IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.

  2010influential reference
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2009cited by this paper
• IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.

  2009cited by this paper
• IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas

  2009cited by this paper
• NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.

  2009cited by this paper
• Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α

  2009cited by this paper
• Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

  2009cited by this paper
• Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

  2009cited by this paper
• IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review

  2008cited by this paper
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2008cited by this paper
• Regulation of singlet oxygen-induced apoptosis by cytosolic NADP+-dependent isocitrate dehydrogenase

  2007cited by this paper
• Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas

  2007cited by this paper
• D-2-Hydroxyglutaric aciduria: Unravelling the biochemical pathway and the genetic defect

  2006cited by this paper
• Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy

  2006cited by this paper
• Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma

  2004cited by this paper
• Promoter Hypermethylation of the DNA Repair Gene O6‐Methylguanine‐DNA Methyltransferase is an Independent Predictor of Shortened Progression Free Survival in Patients with Low‐grade Diffuse Astrocytomas

  2003cited by this paper
• Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.

  2002influential reference
• Pathology and Genetics of Tumours of the Nervous System

  2001cited by this paper
• Expression of hypoxia‐inducible factor 1α in brain tumors

  2000cited by this paper
• Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

  2000cited by this paper
• Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression.

  2000cited by this paper
• Identification by Mutagenesis of Arginines in the Substrate Binding Site of the Porcine NADP-dependent Isocitrate Dehydrogenase*

  2000cited by this paper
• Expression and mutagenesis of mammalian cytosolic NADP+-specific isocitrate dehydrogenase.

  1997cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• The clinical evaluation of chemotherapeutic agents in cancer

  1949cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• Ollier Disease, Acute Myeloid Leukemia, and Brain Glioma: IDH as the Common Denominator

  2024influential citation
• MAPK pathway-targeted therapies for pediatric low grade gliomas

  2023cites this paper
• Update for astrocytomas: medical and surgical management considerations

  2023cites this paper
• Bisulfite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics

  2022cites this paper
• Malignant Progression of Diffuse Low-grade Gliomas: A Systematic Review and Meta-analysis on Incidence and Related Factors

  2022cites this paper
• Bisulfite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics

  2022cites this paper
• Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells

  2022cites this paper
• Clinical impact of IDH1 mutations and MGMT methylation in adult glioblastoma

  2022cites this paper
• Laser Interstitial Thermal Therapy in Grade 2/3 IDH1/2 Mutant Gliomas: A Preliminary Report and Literature Review

  2022influential citation
• Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F]FET PET radiomics

  2021cites this paper
• Genomic prognosticators and extent of resection in molecularly subtyped, WHO grade II and III gliomas - a single institution, nine-year review.

  2021cites this paper
• TERT-Promoter Mutational Status in Glioblastoma – Is There an Association With Amino Acid Uptake on Dynamic 18F-FET PET?

  2021cites this paper
• Immunohistochemical expression of MGMT in gliomas and its role in ascertaining patient survival

  2021cites this paper
• Clinicopathological Correlation of Glioma Patients with respect to Immunohistochemistry Markers: A Prospective Study of 115 Patients in a Tertiary Care Hospital in North India

  2021cites this paper
• Prostate Apoptosis Response-4: a Therapeutic Target for Malignant Gliomas

  2021cites this paper
• Cognitive Functions in Repeated Glioma Surgery

  2020cites this paper
• Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma

  2020cites this paper
• Surgical management of 1p/19q co-deleted oligodendrogliomas WHO grade II and III

  2019cites this paper
• Application of an Artificial Intelligence Algorithm to Prognostically Stratify Grade II Gliomas

  2019cites this paper
• Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era.

  2019cites this paper
• IDH wild-type WHO grade II diffuse low-grade gliomas. A heterogeneous family with different outcomes. Systematic review and meta-analysis

  2018cites this paper
• IDH1, ATRX, and BRAFV600E mutation in astrocytic tumors and their significance in patient outcome in north Indian population

  2018cites this paper
• Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide)

  2018cites this paper
• Folate: Friend or Foe? An investigation into the opposing roles of folate in glioma

  2018cites this paper
• Biological tumour volumes of gliomas in early and standard 20–40 min 18F-FET PET images differ according to IDH mutation status

  2018cites this paper
• Erratum to: Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas

  2017cites this paper
• IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas

  2017cites this paper
• Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss

  2017cites this paper
• Tumor-Specific Approach: Oligodendroglioma (IDH1 Mutated, 1p/19q Deleted)

  2017cites this paper
• Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas

  2016cites this paper
• Potential Utility of Visually AcceSAble Rembrandt Images Assessment in Brain Astrocytoma Grading

  2016cites this paper
• Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology

  2016cites this paper
• 5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas

  2016cites this paper
• Association of The IDH1 C.395G>A (R132H) Mutation with Histological Type in Malay Brain Tumors

  2016influential citation
• Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status

  2016cites this paper
• Impact of Molecular Markers on Personalised-Treatment Concepts in Gliomas

  2016cites this paper
• Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies

  2015cites this paper
• The role of radiotherapy in the management of patients with diffuse low grade glioma

  2015cites this paper
• IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy

  2015cites this paper
• IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO

  2015cites this paper
• Diagnostic, prognostic and predictive relevance of molecular markers in gliomas

  2015cites this paper
• Prognostic Factors in Lobar World Health Organization Grade II Astrocytomas.

  2015cites this paper
• Early treatment of complex located pediatric low‐grade gliomas using iodine‐125 brachytherapy alone or in combination with microsurgery

  2015cites this paper
• Dynamic 18F‐FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses

  2015cites this paper
• ATRX loss-of-function in mouse neuroprogenitor cells as a model of early events in gliomagenesis

  2015cites this paper
• IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma

  2015cites this paper
• The role of neuropathology in the management of patients with diffuse low grade glioma

  2015cites this paper
• Management of patients with recurrence of diffuse low grade glioma

  2015cites this paper
• The role of emerging therapy in the management of patients with diffuse low grade glioma

  2015cites this paper
• Outcome and toxicity profile of salvage low-dose-rate iodine-125 stereotactic brachytherapy in recurrent high-grade gliomas

  2015cites this paper
• Clinicopathologic Characteristics of Brain Tumors are Associated with the Presence and Patterns of TP53 Mutations: Evidence from the IARC TP53 Database

  2014cites this paper
• A clinicopathological and molecular genetic analysis of low-grade glioma in adults

  2014cites this paper
• Title Advanced MR Imaging of Gliomas : An Update Permalink

  2014cites this paper
• Alterations of the RRAS and ERCC1 Genes at 19q13 in Gemistocytic Astrocytomas

  2014cites this paper
• Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas

  2014cites this paper
• Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.

  2014cites this paper
• Epigenetics in human gliomas.

  2014cites this paper
• Impact of Molecular Markers on Personalised-Treatment Concepts in Gliomas

  2014cites this paper
• Dynamic 18F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients

  2014cites this paper
• Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients

  2014cites this paper
• IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma

  2014cites this paper
• The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms

  2013cites this paper
• A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1)

  2013cites this paper
• Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.

  2013cites this paper
• Personalized treatment strategies in glioblastoma: MGMT promoter methylation status

  2013cites this paper
• Advanced MR Imaging of Gliomas: An Update

  2013cites this paper
• What do we know about IDH1/2 mutations so far, and how do we use it?

  2013cites this paper
• Factors influencing overall survival specific to adult low-grade astrocytoma: a population-based study.

  2013cites this paper
• MET Gain in Diffuse Astrocytomas is Associated with Poorer Outcome

  2013cites this paper
• Lessons from next-generation sequencing analysis in hematological malignancies

  2013cites this paper
• Expression of R132H Mutational IDH1 in Human U87 Glioblastoma Cells Affects the SREBP1a Pathway and Induces Cellular Proliferation

  2013cites this paper
• The molecular landscape of diffuse glioma and prospects for biomarker development.

  2013cites this paper
• Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis

  2013cites this paper
• Medikamentöse Therapie von Hirntumoren

  2013cites this paper
• Personalized treatment strategies in glioblastoma: MGMT promoter methylation status

  2013cites this paper
• Molecular predictors of outcome in low-grade glioma.

  2012cites this paper
• Personalized surgical therapy.

  2012cites this paper
• Nuclear karyopherin a2: a novel biomarker for infiltrative astrocytomas

  2012cites this paper
• IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas

  2012cites this paper
• Biomarkers Classification and Therapeutic Decision-Making for Malignant Gliomas

  2012cites this paper
• Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors

  2012cites this paper
• Gliosis Versus Glioma?: Don’t Grade Until You Know

  2012cites this paper
• No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas

  2012cites this paper
• Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma

  2012cites this paper
• Medikamentöse Therapie von Hirntumoren

  2012cites this paper
• Intramedullary pilomyxoid astrocytoma with intracerebral metastasis exhibiting oligoden-droglioma-like features

  2012cites this paper
• Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

  2012cites this paper
• New molecularly targeted therapies for glioblastoma multiforme.

  2012cites this paper
• IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives

  2012cites this paper
• IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma

  2012cites this paper
• IDH 1 and IDH 2 Mutations in Tumorigenesis : Mechanistic Insights and Clinical Perspectives

  2012cites this paper